Dr. Pierre Kory Testifies at Senate Homeland Security Hearing on COV Treatments

Dr. Pierre Kory Testifies at Senate Homeland Security Hearing on COV Treatments

I DO NOT ADVISE ANYONE TO TAKE ANYTHING BEFORE EXTENSIVE REASERCH IS DONE.

Mass treatment with ivermectin

https://www.who.int/bulletin/volumes/82/8/562.pdf

Ivermectin
https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/

A five-day course of ivermectin for the treatment of COV

https://pubmed.ncbi.nlm.nih.gov/33278625/

Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108190/

Ivermectin in the treatment of COV protocol for a systematic review and meta-analysis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450968/

Safety of high-dose ivermectin: a systematic review and meta-analysis
https://pubmed.ncbi.nlm.nih.gov/31960060/

Who’s Afraid Of Ivermectin?
https://www.acsh.org/news/2021/05/04/who%E2%80%99s-afraid-ivermectin-15529

The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds

Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection

https://pubs.rsc.org/en/content/articlehtml/2021/cp/d1cp02967c

the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket:

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents

https://www.nature.com/articles/s42003-020-01577-x.pdf

as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration.

Development, validation, and approval of COV specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly.

Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COV drugs: designing, docking and molecular dynamics simulation study

https://pubs.rsc.org/en/content/articlehtml/2020/ra/d0ra06379g

From the docking analysis, ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds. Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373590/

Ritonavir, C37H48N6O5S2

Ivermectin, C48H74O14

Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/

We have documented an intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6.

PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,

https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

Risk of virus developing resistance to PF-07321332

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2

https://www.frontiersin.org/articles/10.3389/fmicb.2020.592908/full

With SARS-CoV-2 S Spike protein

Ivermectin showed high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2.

In agreement to our findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor

Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein)

The docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein–ligand interactions

Binding Interactions of Selected Drugs With Human ACE-2 Protein

that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein–ligand interactions

With SARS-CoV-2 S Glycoprotein

Ivermectin showed the highest binding affinity to the predicted active site of the protein

With SARS-CoV-2 Nsp14 Protein

ivermectin showed the highest binding affinity (MolDock score −212.265) and protein–ligand interactions

Binding Interactions of Selected Drugs With SARS-CoV-2 PLpro

Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein–ligand interactions

Original link by Bloomberg Quicktake

https://www.youtube.com/watch?v=k8RyV3VEDKI&t=1882s